Article

COVID-19: Sun Pharmaceuticals business update

Author(s):

Mark Hagler

Mark Hagler, senior vice president, head of Ophthalmics, Oncology and LTC, at Sun Pharmaceuticals, shares a business update on how the company has responded and continued operations during the coronavirus pandemic.
 

 

 

See more coronavirus coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
Related Content
Health Canada approves aflibercept biosimilar Aflivu
July 8th 2025

Health Canada approves aflibercept biosimilar Aflivu

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

A look at the vorolanib intravitreal insert compared with aflibercept for DME
July 8th 2025

A look at the vorolanib intravitreal insert compared with aflibercept for DME

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada
July 8th 2025

LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada

PER-001 shows vision restoration in glaucoma and DR in phase 2a trials
July 7th 2025

PER-001 shows vision restoration in glaucoma and DR in phase 2a trials

© 2025 MJH Life Sciences

All rights reserved.